Arja ter Elst

2.6k total citations · 1 hit paper
61 papers, 1.8k citations indexed

About

Arja ter Elst is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Arja ter Elst has authored 61 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 21 papers in Pulmonary and Respiratory Medicine and 20 papers in Oncology. Recurrent topics in Arja ter Elst's work include Acute Myeloid Leukemia Research (17 papers), Lung Cancer Treatments and Mutations (15 papers) and Cancer Genomics and Diagnostics (14 papers). Arja ter Elst is often cited by papers focused on Acute Myeloid Leukemia Research (17 papers), Lung Cancer Treatments and Mutations (15 papers) and Cancer Genomics and Diagnostics (14 papers). Arja ter Elst collaborates with scholars based in Netherlands, United States and Russia. Arja ter Elst's co-authors include Eveline S.J.M. de Bont, Willem A. Kamps, Hendrik J.M. de Jonge, Robert M.W. Hofstra, Gerard J. te Meerman, Frans Gerbens, Elisabeth G.E. de Vries, Rudolf S.N. Fehrmann, Ate G.J. van der Zee and Kim R. Kampen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Arja ter Elst

60 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Evidence Based Selection of Housekeeping Genes

2007 611 citations Hendrik J.M. de Jonge, Rudolf S.N. Fehrmann et al. PLoS ONE profile →

Peers

Countries citing papers authored by Arja ter Elst

Since Specialization

Citations

This map shows the geographic impact of Arja ter Elst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arja ter Elst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arja ter Elst more than expected).

Fields of papers citing papers by Arja ter Elst

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arja ter Elst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arja ter Elst. The network helps show where Arja ter Elst may publish in the future.

Co-authorship network of co-authors of Arja ter Elst

This figure shows the co-authorship network connecting the top 25 collaborators of Arja ter Elst. A scholar is included among the top collaborators of Arja ter Elst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arja ter Elst. Arja ter Elst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	BRCA1/2 Testing Landscape in Ovarian Cancer: A Nationwide, Real-World Data Study 2024 ·Cancers ·(unknown), Joost Bart, Marian J.E. Mourits, Stefan M. Willems, Annemieke H. van der Hout, Arja ter Elst, Geertruida H. de Bock	2
2	Levels of circulating tumor DNA correlate with tumor volume in gastro‐intestinal stromal tumors: an exploratory long‐term follow‐up study 2024 ·Molecular Oncology ·(unknown), (unknown), (unknown), (unknown), Ron H.J. Mathijssen, Neeltje Steeghs, Hans Gelderblom, Ingrid M.E. Desar, (unknown), Arja ter Elst, Ed Schuuring, Anna K.L. Reyners	1
3	BRCA1/2 testing rates in epithelial ovarian cancer: a focus on the untested patients 2023 ·International Journal of Gynecological Cancer ·(unknown), Marian J.E. Mourits, Joost Bart, Arja ter Elst, (unknown), Annemieke H. van der Hout, (unknown), Geertruida H. de Bock	1
4	Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors 2021 ·Molecular Oncology ·Paul van der Leest, Birgitta I. Hiddinga, (unknown), (unknown), (unknown), Arja ter Elst, Wim Timens, Harry J.M. Groen, Léon C.L.T. van Kempen, T. Jeroen N. Hiltermann, Ed Schuuring	23
5	Comparison of Circulating Cell-Free DNA Extraction Methods for Downstream Analysis in Cancer Patients 2020 ·Cancers ·Paul van der Leest, (unknown), Arja ter Elst, Léon C.L.T. van Kempen, (unknown), (unknown), (unknown), Menno Tamminga, Harry J.M. Groen, Anna K.L. Reyners, Ed Schuuring	46
6	1968P The clinical effect of concurrent oncogenic gene mutations in BRAF p.(V600E)-mutated NSCLC treated with dabrafenib and trametinib 2020 ·Annals of Oncology ·(unknown), (unknown), Klaas Kok, Arja ter Elst, Ed Schuuring, Léon C.L.T. van Kempen, Wim Timens, T. Jeroen N. Hiltermann, Harry J.M. Groen, Anke van den Berg, Anthonie J. van der Wekken	1
7	Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation 2020 ·Lung Cancer ·(unknown), (unknown), Klaas Kok, Arja ter Elst, Ed Schuuring, Léon C.L.T. van Kempen, Wim Timens, T. Jeroen N. Hiltermann, Harry J.M. Groen, Anke van den Berg, Anthonie J. van der Wekken	39
8	Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material 2020 ·BMC Cancer ·Elisabeth M. P. Steeghs, Leonie I. Kroeze, Bastiaan B.J. Tops, Léon C.L.T. van Kempen, Arja ter Elst, (unknown), (unknown), (unknown), Erik A. M. Jansen, Petra M. Nederlof, Ed Schuuring, Marjolijn J. L. Ligtenberg, Astrid Eijkelenboom	24
9	VEGFC Antibody Therapy Drives Differentiation of AML 2018 ·Cancer Research ·Kim R. Kampen, Frank J.G. Scherpen, Hasan Mahmud, Arja ter Elst, André B. Mulder, Victor Guryev, (unknown), Kim De Keersmaecker, Linda Smit, Steven M. Kornblau, Eveline S.J.M. de Bont	11
10	Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification 2018 ·Frontiers in Oncology ·(unknown), Arja ter Elst, Nils A. ‘t Hart, Harry J.M. Groen, Ed Schuuring, Anthonie J. van der Wekken	3
11	Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung Cancer 2016 ·PLoS ONE ·Ali Saber, Anthonie J. van der Wekken, (unknown), Maarten van den Berge, Wim Timens, Ed Schuuring, Arja ter Elst, Anke van den Berg, T. Jeroen N. Hiltermann, Harry J.M. Groen	9
12	Effect of IKZF1 deletions on signal transduction pathways in Philadelphia chromosome negative pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) 2015 ·Experimental Hematology and Oncology ·(unknown), Frank J.G. Scherpen, Arja ter Elst, Victor Guryev, Frank N. van Leeuwen, Eveline S.J.M. de Bont	1
13	Impaired Long-Term Expansion and Self-Renewal Potential of Pediatric Acute Myeloid Leukemia–Initiating Cells By PTK787/ZK 222584 2013 ·Molecular Cancer Research ·(unknown), Arja ter Elst, Kim R. Kampen, (unknown), Willem A. Kamps, Jan Jacob Schuringa, Eveline S.J.M. de Bont	5
14	Repression of Vascular Endothelial Growth Factor Expression by the Runt-Related Transcription Factor 1 in Acute Myeloid Leukemia 2011 ·Cancer Research ·Arja ter Elst, Bin Ma, Frank J.G. Scherpen, Hendrik J.M. de Jonge, (unknown), Albertus T.J. Wierenga, Jan Jacob Schuringa, Willem A. Kamps, Eveline S.J.M. de Bont	27
15	High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia 2010 ·Blood ·Hendrik J.M. de Jonge, Peter J.M. Valk, Nic J.G.M. Veeger, Arja ter Elst, Monique L. den Boer, Jacqueline Cloos, Válerie de Haas, Marry M. van den Heuvel‐Eibrink, Gertjan J.L. Kaspers, C. Michel Zwaan, Willem A. Kamps, Bob Löwenberg, Eveline S.J.M. de Bont	74
16	Mesenchymal Stem Cells Contribute to Tumor Cell Proliferation by Direct Cell-Cell Contact Interactions 2010 ·Cancer Investigation ·(unknown), Arja ter Elst, (unknown), Willem A. Kamps, Eveline S.J.M. de Bont	41
17	Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target Discovery 2009 ·Cancer Research ·Arend H. Sikkema, Sander H. Diks, Wilfred F.A. den Dunnen, Arja ter Elst, Frank J.G. Scherpen, Eelco W. Hoving, Rob Ruijtenbeek, Piet J. Boender, Rik de Wijn, Willem A. Kamps, Maikel P. Peppelenbosch, Eveline S.J.M. de Bont	104
18	Endogenous Vascular Endothelial Growth Factor-C Expression Is Associated with Decreased Drug Responsiveness in Childhood Acute Myeloid Leukemia 2008 ·Clinical Cancer Research ·Hendrik J.M. de Jonge, (unknown), Arja ter Elst, H. Marike Boezen, Frank J.G. Scherpen, Jessica C.A. Bouma-ter Steege, Gertjan J.L. Kaspers, Bianca F. Goemans, Ursula Creutzig, Martin Zimmermann, Willem A. Kamps, Eveline S.J.M. de Bont	18
19	Evidence Based Selection of Housekeeping Genes breakdown → 2007 ·PLoS ONE ·Hendrik J.M. de Jonge, Rudolf S.N. Fehrmann, Eveline S.J.M. de Bont, Robert M.W. Hofstra, Frans Gerbens, Willem A. Kamps, Elisabeth G.E. de Vries, Ate G.J. van der Zee, Gerard J. te Meerman, Arja ter Elst	611
20	Analysis of a new homozygous deletion in the tumor suppressor region at 3p12.3 reveals two novel intronic noncoding RNA genes 2006 ·Genes Chromosomes and Cancer ·Debora Angeloni, Arja ter Elst, Ming Wei, Anneke Y. van der Veen, Э. А. Брага, Е.А. Климов, Tineke Timmer, (unknown), Michael I. Lerman, Charles H.C.M. Buys	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact